348 Relationship between MRI Lesion Count and B Cell Count Reduction under Ofatumumab Treatment M. Savelieva (Novartis Pharma AG, Basel, Switzerland), J. Kahn (Novartis Pharma AG, Basel, Switzerland), E. Wallstroem (Novartis Pharma AG, Basel, Switzerland), D. Leppert (Novartis Pharma AG, Basel, Switzerland). |
Labels: AAN2017, Ofatumumab